Because of the good results of anti CD22 (inotuzumab ozogamycin), in combination with low-intensity chemotherapy [e.g., minihyperCVD (cyclophosphamide, vincristine, dexamethasone)] for older patients with ALL Ph-negative in first line therapy, this approach could be considered as an alternative, but it depends on the availability and the cost of anti CD22. Here, CD22 is linked to acute lymphoblastic leukemia.